CALI: calcimedica.com Kompaniya qiymatining sof foydaga nisbati
CalciMedica, Inc. (CALI) immunoterapiya agentlarini, xususan, o'pka yallig'lanishi va pankreatitga qarshi dori vositalarini bozorga olib chiqish orqali daromad keltiradi. Ushbu grafik 0.00 miqdoridagi bozor bahosini aks ettiradi. Kompaniya klinik tahlillar uchun dasturiy robotlarni joriy qilmoqda va molekulalarni skrining qilishni avtomatlashtirmoqda. Shoshilinch yordam terapiyasi sohasidagi innovator sifatidagi maqomi, ko'p a'zoli yetishmovchilikning oldini olish orqali brendning intensiv terapiya mutaxassislari orasida tanilishiga yordam bermoqda.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_CALI_-_CalciMedica-Inc._-_PE-Multiple "CALI: CalciMedica Corp Biznesning o‘zini qoplash muddati 11.10.2024 - 17.10.2026 | 👁️GURU.Markets👁️")
CalciMedica Corp (CALI) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati CalciMedica, Inc.|CALI - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati calcimedica.com|CALI - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati CalciMedica Inc|CALI - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz CalciMedica|Tezkor likvidlik ko‘rsatkichi calcimedica.com
- foyda va bozor multiplikatorlari tafsilotlari:
CALI - Sof foyda|Prognoz qilingan kelajakdagi foyda CalciMedica, Inc.|CALI - Narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati CalciMedica, Inc.|CALI - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti CalciMedica Inc|CALI - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda CalciMedica|CALI - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi calcimedica.com|CALI - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi CalciMedica, Inc.
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:CalciMedica CALI
P/E koeffitsiyenti bozor kapitalizatsiyasining sof foydaga nisbati sifatida hisoblanadi va yillik daromadning bir dollari uchun to'lanadigan xarajatni o'lchaydi. Ushbu nisbat konservativ kapitalga spekulyativ pufaklarni filtrlash va haddan tashqari qizigan aktivlar uchun ortiqcha to'lov qilishdan qochish imkonini beradi. Qat'iy FDA nazorati va ventura kapitali oliqimlariga bog'liq bo'lgan CalciMedica, Inc. (CALI) uchun ushbu metrika Auxora patentlariga bo'lgan bozor kutganlarini aks ettiradi. P/E baholash tendentsiyasini tahlil qilish orqali investor kompaniyaning biotexnologik istiqbollari qanchalik haddan tashqari yuqori baholanganini aniqlashi mumkin.
Muhim raqobatchilar
P/E multiplikatori Argenx|Narx-foyda koeffitsiyenti BNTX (BioNTech Group)|ABVX (abivax.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (admabiologics.com)|Biznesning o‘zini qoplash muddati protagonist-inc.com (PTGX)|IMVT - Narxning foydaga nisbati|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Narx-foyda koeffitsiyenti|Grifols Biemat (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotechnologies|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori auriniapharma.com|Narxning foydaga nisbati BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Narx-foyda multiplikatori|P/E multiplikatori DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Kapitalizatsiyaning foydaga nisbati|AbCellera Biologics - P/E multiplikatori|tourmalinebio.com - Bozor narxining sof foydaga nisbati|Precigen (PGEN) - Narxning foydaga nisbati|Pharming Group - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Nektar Therapeutics Inc|UPB (Upstream Pharma) - Bozor narxining sof foydaga nisbati|P/E multiplikatori ZBIO|P/E multiplikatori immunome.com (IMNM)|P/E multiplikatori GOSS (gossamerbio.com)|Biznesning o‘zini qoplash muddati KalVista Pharma (KALV)|SEPN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E multiplikatori|ATXS (Astria Therapeutics, Inc.) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Aerovate Therapeutics - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati ACRS|Kyverna Therapeutics, Inc - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati TLSA|CABA: P/E multiplikatori|Narx-foyda koeffitsiyenti Ventyx Bio|Narxning foydaga nisbati Theratechnologies, Inc.|Kapitalizatsiyaning foydaga nisbati Avalo Therapeutics AVTX|P/E multiplikatori ELDN|AGEN (Agenus, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Kapitalizatsiyaning foydaga nisbati|ATYR: Narx-foyda koeffitsiyenti|adagene.com (ADAG) - Narx-foyda koeffitsiyenti|Ikena Oncology (IMA) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Shattuck Labs, Inc.|Narxning foydaga nisbati equilliumbio.com|Narx-foyda koeffitsiyenti connectbiopharm.com (CNTB)|P/E multiplikatori IMUX|Biznesning o‘zini qoplash muddati Atara Bio|Narxning foydaga nisbati InflaRx N.V. IFRX|X4 Pharmaceuticals - Narxning foydaga nisbati|ACET: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati CELU (celularity.com)|INMB: P/E multiplikatori|BRNS: Bozor narxining sof foydaga nisbati|KZR (Kezar Life Sciences, Inc.) - P/E multiplikatori|SAB Biotherapeutics Inc. (SABS) - Biznesning o‘zini qoplash muddati|P/E multiplikatori AKTX|Narxning foydaga nisbati ENLV (Enlivex Therapeutics Ltd)|Narxning foydaga nisbati Q32 Bio Inc. QTTB|GOVX - Narx-foyda koeffitsiyenti|EDSA - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati iBio|CARM: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati XTLB (XTL Biopharmaceuticals, Ltd.)|Narxning foydaga nisbati boltbio.com|P/E multiplikatori HCW Biologics|P/E multiplikatori APVO|AIM - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ADTX (Aditxt Inc.)|Biznesning o‘zini qoplash muddati GRI Bio, Inc. (GRI)|XRTX - Narxning foydaga nisbati|reshapelifesciences.com (HIND) - Narx-foyda koeffitsiyenti|REVB: P/E multiplikatori|Indaptus Therapeutics, Inc. - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Scinai|affimed.com - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati allakos.com (ALLK)|P/E multiplikatori HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Narx-foyda koeffitsiyenti|iTeos Therapeutics, Inc. (ITOS) - Kapitalizatsiyaning foydaga nisbati|OCEA: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E multiplikatori
